Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

BACKGROUND: In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mecenate, Fabrizio, Pellicelli, Adriano M, Barbaro, Giuseppe, Romano, Mario, Barlattani, Angelo, Mazzoni, Ettore, Bonaventura, Maria Elena, Nosotti, Lorenzo, Arcuri, Pasquale, Picardi, Antonio, Barbarini, Giorgio, D'Ambrosio, Cecilia, Paffetti, Amerigo, Andreoli, Arnaldo, Soccorsi, Fabrizio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837223/
https://www.ncbi.nlm.nih.gov/pubmed/20170514
http://dx.doi.org/10.1186/1471-230X-10-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837223/
https://www.ncbi.nlm.nih.gov/pubmed/20170514
http://dx.doi.org/10.1186/1471-230X-10-21

Ejemplares similares